Huahai Pharmaceutical

Huahai Pharmaceutical Takes Human Health as Its Mission, Dedicated to Providing High-Quality Healthcare Products to Patients Worldwide While Continuously Improving Product Accessibility and Enhancing the Quality of Life for the Public. Established in 1989, Huahai Pharmaceutical is Headquartered in Zhejiang, China. The Group Now Employs Over 7,000 People and Has More Than 30 Subsidiaries Around the Globe (Including the United States, Japan, Russia, Spain, India, etc.). Its Business Covers Multiple Fields Such as Chemical Pharmaceuticals, Biopharmaceuticals, Pharmaceutical Packaging, Trade, and Distribution. It Has Built Long-Term Cooperative Relationships with Over 500 Pharmaceutical Companies Worldwide and Provides Healthcare Products to Nearly 200 Countries and Regions. The Group’s Product Portfolio Includes Cardiovascular, Psychiatric, Antiviral, and Antihistamine Areas, Making It One of the Leading Global Manufacturers of Cardiovascular and Psychiatric Healthcare Products. As a Pioneer in the Internationalization of China's Pharmaceutical Industry, Huahai Pharmaceutical Was the First Chinese Pharmaceutical Company to Obtain FDA Approval for Formulation Quality in the United States and Independently Hold ANDA Registrations. It Was Also the First Chinese Pharmaceutical Company to Achieve Large-Scale Formulation Sales in the United States, Establishing an Image of Chinese Pharmaceutical Quality in the High-End Global Pharmaceutical Market. Leveraging Its Own International Platform, the Group, With a Strategic Perspective on the Global Market, Guides Other Local Pharmaceutical Companies in China to Expand Overseas and Enter the Global Arena, Striving for the Rise of China's Pharmaceutical Industry.